Press release
Limb Girdle Muscular Dystrophy (LGMD) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | ML Bio Solutions, Asklepios, Sarepta, Atamyo, Edgewise, Vita Therapeutics, BridgeBio, Hansa Biopharma
"Limb Girdle Muscular Dystrophy (LGMD) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Limb Girdle Muscular Dystrophy Therapeutics Market.
The report provides a detailed description of the Limb Girdle Muscular Dystrophy drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Limb Girdle Muscular Dystrophy Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Limb Girdle Muscular Dystrophy (LGMD) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Limb Girdle Muscular Dystrophy therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Limb Girdle Muscular Dystrophy treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Limb Girdle Muscular Dystrophy drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Limb Girdle Muscular Dystrophy treatment market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More about the Clinical and Commercial Development Activities in the Limb Girdle Muscular Dystrophy Therapeutics Domain:
https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Limb Girdle Muscular Dystrophy Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Limb Girdle Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Request for Sample PDF to Understand More About the Limb Girdle Muscular Dystrophy Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Limb Girdle Muscular Dystrophy (LGMD) Therapeutics Analysis
There are approx. 20+ key companies developing therapies for Limb Girdle Muscular Dystrophy. Currently, ML Bio Solutions is leading the therapeutics market with its Limb Girdle Muscular Dystrophy drug candidates in the most advanced stage of clinical development.
Limb Girdle Muscular Dystrophy (LGMD) Companies in the Therapeutics Market Include:
• ML Bio Solutions
• Asklepios BioPharmaceutical
• Sarepta Therapeutics, Inc.
• Atamyo Therapeutics
• Edgewise Therapeutics
• Vita Therapeutics
• BridgeBio Pharma
• Hansa Biopharma
And Many Others
Emerging and Marketed Limb Girdle Muscular Dystrophy (LGMD) Therapies Covered in the Report Include:
• BBP-418: ML Bio Solutions
• LION-101: Asklepios BioPharmaceutical
And Many More
Get an in-depth Assessment of the Emerging Therapies and Limb Girdle Muscular Dystrophy Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Limb Girdle Muscular Dystrophy Current Treatment Patterns
4. Limb Girdle Muscular Dystrophy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Limb Girdle Muscular Dystrophy Late-Stage Products (Phase-III)
7. Limb Girdle Muscular Dystrophy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Limb Girdle Muscular Dystrophy Discontinued Products
13. Limb Girdle Muscular Dystrophy Product Profiles
14. Limb Girdle Muscular Dystrophy Companies
15. Limb Girdle Muscular Dystrophy Drugs
16. Dormant and Discontinued Products
17. Limb Girdle Muscular Dystrophy Unmet Needs
18. Limb Girdle Muscular Dystrophy Future Perspectives
19. Limb Girdle Muscular Dystrophy Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Limb Girdle Muscular Dystrophy (LGMD) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | ML Bio Solutions, Asklepios, Sarepta, Atamyo, Edgewise, Vita Therapeutics, BridgeBio, Hansa Biopharma here
News-ID: 3111261 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Limb
Critical Limb Ischemia Pipeline: Advancing Regenerative Therapies and Novel Inte …
The treatment landscape for Critical Limb Ischemia (CLI), the most severe form of peripheral arterial disease, is evolving rapidly as the limitations of conventional revascularization and amputation drive demand for novel therapeutic approaches. Breakthroughs in angiogenesis, stem cell therapies, gene therapy, and immunomodulation are reshaping the future of CLI management, offering hope for tissue regeneration and improved limb salvage outcomes.
DelveInsight's "Critical Limb Ischemia - Pipeline Insight, 2025" provides an in-depth…
Limb Prosthetics Market Size And Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- Limb Prosthetics Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2020 to 2027.
Limb Prosthetics Market Growth Driver
The limb prosthetics market is experiencing significant growth, driven by several key factors, including the rising prevalence of limb loss due to diabetes, vascular diseases, and traumatic injuries. As…
Pediatric Lower Limb Prosthetics Market
The "Pediatric Lower Limb Prosthetics Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Pediatric Lower Limb Prosthetics Market, 2024-2031
Verified Market Research's most recent report, "Pediatric Lower Limb Prosthetics Market: Global Industry Trends, Share, Size, Growth, Opportunity and…
Limb Prosthetics Market 2024 Strategic Assessment
In recent years, the global Limb Prosthetics Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Limb Prosthetics Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five…
Lower Limb Rehabilitation Exoskeleton Robot | WALKBOT
The exoskeleton robotic rehabilitation devices made by WALKBOT provide robot-assisted gait training rehabilitation systems for musculoskeletal disabilities.
Walkbot Advanced solutions
The Walkbot, lower limb rehabilitation robot provides exciting customized 3-dimensional augmented reality exercise games so that their clients actually do not perceive the gait training as a form of therapy. Rather, they enjoy walking in interactive and ecologically natural or virtual environments as used by the software.
Game-Like Rehabilitation Training: Go World immerses…
Critical Limb Ischemia - Drug Pipeline Landscape, 2022
Critical limb ischemia is a serious form of peripheral arterial disease, or PAD where severe blockage in the arteries of the lower extremities (hands, feet and legs) occurs, which markedly reduces blood-flow. It results in severe pain and even skin ulcers or sores.
Peripheral artery disease causes chronic limb-threatening ischemia. Other causes of limb ischemia include embolisms, trauma and compartment syndrome.
The most common symptom of critical limb ischemia is ischemic…
